- Home
- VSTM
VSTM
Verastem Inc.
as 12-20-2024 3:44pm EST
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 239.9M | IPO Year: | 2012 |
| Target Price: | $12.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.10 - $14.22 | Next Earning Date: | 11-06-2024 |
| Revenue: | $10,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 53.90% |
Stock Insider Trading Activity of Verastem Inc. (VSTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Calkins Daniel | VSTM | Chief Financial Officer | Oct 7 '24 | Sell | $2.86 | 6 | $17.16 | 47,461 |
Latest Verastem Inc. News
VSTM Breaking Stock News: Dive into VSTM Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
MT Newswires
4 days ago
Mizuho Raises Price Target on Verastem to $9 From $7, Keeps Outperform Rating
Business Wire
4 days ago
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Business Wire
a month ago
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
Associated Press Finance
2 months ago
Verastem: Q3 Earnings Snapshot
Business Wire
2 months ago
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Pharmaceutical Technology
2 months ago
Verastem Oncology submits NDA for ovarian cancer treatment
MT Newswires
2 months ago
Verastem Completes Rolling NDA Submission to US FDA for Drug Combination to Treat Rare Ovarian Cancer
Compare VSTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VSTM Verastem Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.